Biotech veterans John Maraganore and Clive Meanwell have had a hand in multiple paradigm-shifting medicines over the last three decades. But on Tuesday, the duo launched a new venture they say may be their most important work to date.
The venture, Corsera Health, is a small company with a big goal: Create a world without cardiovascular disease. Corsera is developing an AI tool called Klotho Health that will predict a person’s likelihood of developing cardiovascular disease. In tandem with that effort, Corsera is working on an RNAi drug that targets PCSK9 — one of the known drivers of heart disease — and angiotensinogen, which influences blood pressure.
The company plans to start a clinical trial of that drug by the end of the year.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.